Big news on the Valeant Pharma front. Quite a few hedge-funds are in deep on this stock, including Ackman’s Pershing Square Capital.
Valeant is under scrutiny for its business and accounting practices.
Read Full Story: Valeant cuts guidance, shares fall – Business Insider
